Ryan Zimmerman, an analyst from BTIG, maintained the Buy rating on Alcon. The associated price target is $91.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Zimmerman has given his Buy rating due to a combination of factors including Alcon’s strategic initiatives and market opportunities. The company has launched a head-to-head clinical trial to compare its SYSTANE PRO product with Bausch + Lomb’s MIEBO, aiming to establish its efficacy in treating evaporative dry eye disease. This trial is expected to bolster Alcon’s clinical evidence and enhance its competitive position in the dry eye market, which is sizable and growing.
Additionally, Alcon’s valuation is appealing, with a price target based on a multiple that is a discount to its historical average, suggesting potential for share price recovery. The company’s top-line growth and operating margin expansion are expected to improve as it progresses into the fiscal year 2026, further supporting the Buy rating.
In another report released on November 18, KeyBanc also reiterated a Buy rating on the stock with a $91.00 price target.